James Randall Randy Owen

James Randall “Randy” Owen has nearly 20 years of biopharma industry leadership experience in neuroscience drug development. Before joining Navitor, Dr. Owen served as Senior Vice President, Clinical Development and Chief Medical Officer at Acadia Pharmaceuticals Inc, where he led the development of pimavanserin, a 5HT2a inverse agonist, for the treatment of Parkinson’s disease psychosis as well as dementia-related psychosis, depression, and schizophrenias.

Prior to Acadia, he served as Vice President, U.S. Clinical Affairs at Lundbeck LLC, where he directed the evaluation of compounds across a range of neurological and psychiatric disorders, including pediatric epilepsies, stroke, Alzheimer’s disease, and neurogenic orthostatic hypotension.

Earlier in his career, he served in positions of increasing responsibility at Abbott (now Abbvie) and Merck, where he worked on an array of neuroscience compounds, including substance P antagonism and GABA subtype selective modulators. He also served as Group Director, Global Clinical Research at Bristol-Myers Squibb Company where he co-led the life-cycle management of aripiprazole during a period of product extensions in psychiatric indications in the United States and Europe.